Insulin Aspart 30% + Insulin Aspart Protamine 70%

Insulin Aspart 30% + Insulin Aspart Protamine 70% is a premixed insulin preparation used to help control high blood glucose levels in people with diabetes mellitus. It contains two forms of insulin aspart in a fixed ratio. The 30% soluble insulin aspart component acts rapidly to reduce the rise in blood glucose associated with meals, while the 70% protamine-crystallised insulin aspart component is absorbed more slowly and provides a more prolonged glucose-lowering effect. Both components work by binding to insulin receptors, promoting glucose uptake by muscle and fat cells and reducing glucose production by the liver. This combination can help manage both meal-related and between-meal blood glucose levels, although its fixed composition does not allow the two components to be adjusted independently. The medicine is supplied as a suspension for subcutaneous injection, commonly in cartridges or prefilled pens. The dose and injection schedule are individualised according to glucose measurements, meal patterns, activity, other medicines, and treatment goals. Correct resuspension, injection technique, meal timing, storage, and regular glucose monitoring are important for safe use. The most important safety concern is hypoglycaemia, or low blood glucose. Treatment should be supervised by a qualified healthcare professional, and the product is not intended for treating diabetic ketoacidosis.

Insulin aspart is a recombinant insulin analogue developed to act more rapidly after subcutaneous injection than regular human insulin. In this premixed formulation, soluble insulin aspart is combined with protamine-crystallised insulin aspart to provide rapid and intermediate-duration activity in a fixed 30:70 ratio. The European Medicines Agency records European Union authorisation for the NovoMix insulin range, including NovoMix 30, in 2000. In the United States, the related 70% insulin aspart protamine and 30% soluble insulin aspart product, NovoLog Mix 70/30, received initial approval in 2001. These formulations contain the same proportions of the two insulin components, although their naming order differs. Clinical development and product information have evaluated premixed insulin for improving glycaemic control in people with diabetes, including use alongside other glucose-lowering medicines in selected patients with type 2 diabetes. Regulatory indications and approved ages vary by product and jurisdiction, so the locally authorised prescribing information should be checked before use.

Insulin Aspart 30% + Insulin Aspart Protamine 70% is used to improve blood glucose control in diabetes mellitus when insulin treatment is required. Depending on the specific product and local authorisation, it may be used in adults and in eligible younger patients. In type 2 diabetes, it may be prescribed alone or together with selected oral glucose-lowering medicines or other approved therapies when clinically appropriate. Some products with this formulation are authorised for use from 10 years of age, while the United States label for NovoLog Mix 70/30 specifies adults. The rapid-acting component helps control meal-related glucose rises, while the protamine-containing component provides a longer period of insulin activity. Because both components are combined in a fixed ratio, the preparation may not suit every insulin requirement. It is not recommended for treating diabetic ketoacidosis, which requires urgent medical management and an appropriate insulin regimen.

Insulin Aspart 30% + Insulin Aspart Protamine 70% is administered by subcutaneous injection, usually into the abdomen, thigh, upper arm, or buttock, according to the product instructions. It should not be administered intravenously or used in an insulin pump unless the specific product is expressly authorised for that use. The dose and schedule must be individualised by the treating healthcare professional according to blood glucose readings, meals, physical activity, other medicines, and treatment response. Depending on the product and the patient's needs, injections may be scheduled once or more than once daily around meals. Some product labels permit administration shortly before a meal; patients should follow the timing specified for their own medicine. Before use, the suspension must be resuspended according to the instructions until it appears uniformly white and cloudy. Patients should not change their dose, switch insulin products, or alter injection timing without medical guidance. Blood glucose should be monitored regularly, particularly after starting treatment or changing the dose, formulation, injection site, meal routine, or activity level.

The most common side effect is hypoglycaemia, which may cause sweating, trembling, hunger, dizziness, headache, palpitations, difficulty concentrating, or confusion. Other possible effects include weight gain, redness, swelling, itching, bruising, or discomfort at the injection site. Repeated injections into the same area may cause changes in the fatty tissue under the skin, including thickening or indentations, which can affect insulin absorption. Mild swelling may occur when insulin treatment begins or is adjusted. The frequency and severity of side effects vary with the dose, meal intake, physical activity, and individual response. Patients should learn how to recognise and promptly treat low blood glucose and should discuss persistent injection-site reactions, unexplained glucose fluctuations, or recurring symptoms with their healthcare professional.

Severe hypoglycaemia can cause seizures, loss of consciousness, or death and requires urgent treatment. Serious allergic reactions are uncommon but may involve widespread rash, facial or throat swelling, or difficulty breathing. Changes in insulin dose, product, injection technique, meal timing, physical activity, or other medicines can lead to dangerous changes in blood glucose and require closer monitoring. Low blood potassium can occur with insulin treatment, particularly in people at increased risk or receiving medicines that reduce potassium levels. Insulin use may also cause fluid retention, and in some circumstances swelling or worsening heart failure may occur, especially when combined with certain glucose-lowering medicines such as thiazolidinediones. The medicine should not be used during an episode of hypoglycaemia or by a person with a known serious allergy to its ingredients. It is not intended to treat diabetic ketoacidosis. Treatment changes, temporary interruption, or discontinuation should be directed by a healthcare professional, as stopping insulin without an appropriate alternative can cause severe hyperglycaemia.

Blood glucose should be monitored more frequently in patients with kidney or liver impairment, changes in diet or activity, acute illness, or a history of severe hypoglycaemia or reduced awareness of low blood glucose. Older adults and patients who depend on caregivers may need additional support with dose administration and symptom recognition. Pregnancy and breastfeeding require individualised diabetes management and close clinical supervision. Medicines such as other glucose-lowering agents, some antidepressants, salicylates, and certain blood pressure medicines may increase insulin's glucose-lowering effect, while corticosteroids, some diuretics, thyroid hormones, and sympathomimetic medicines may raise blood glucose or alter insulin requirements. Beta-blockers may mask some warning signs of hypoglycaemia. Alcohol can also increase the risk of low blood glucose. Injection sites should be rotated within the recommended body region to reduce tissue changes and unpredictable absorption. Patients should not share insulin pens or needles, even if the needle is changed. The suspension should be stored and handled according to the product-specific instructions and must not be frozen.

Before treatment, review the patient's diabetes history, current medicines, meal schedule, hypoglycaemia risk, injection technique, and ability to monitor glucose. Explain that this is a premixed formulation with a fixed ratio of rapid-acting and intermediate-acting insulin, so the two components cannot be adjusted independently. Demonstrate the correct resuspension procedure and confirm that the suspension looks uniformly white and cloudy before injection. Reinforce product-specific meal timing, dose recording, injection-site rotation, safe sharps disposal, and appropriate storage. Provide clear instructions for recognising and managing hypoglycaemia, including when emergency assistance is required. Review glucose records after treatment initiation or dose changes and reassess the regimen during illness, changes in eating patterns, increased physical activity, or introduction of interacting medicines. When switching from another insulin, use the relevant local product information and arrange closer monitoring during the transition. Pharmacists and other care team members should verify the exact formulation and concentration to reduce medication errors and ensure that patients understand their prescribed device.